MarketPulse
C

$CLDI

3 articles found
1 positive
0 negative
2 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Calidi Biotherapeutics Raises $6M in Public Offering, Exercises Full Warrant Overallotment

Calidi Biotherapeutics closed a $6 million underwritten public offering, issuing 12.1 million shares and Series J, K, L warrants with $0.50 exercise prices.
CLDIwarrantspublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Calidi Biotherapeutics Launches Public Offering to Bolster Growth

Calidi Biotherapeutics launches underwritten public offering of common stock and warrants, with Ladenburg Thalmann managing the raise for working capital and corporate purposes.
CLDIwarrantspublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Calidi Biotherapeutics Advances Tumor-Targeted BiTE Platform Toward Clinical Development

Calidi Biotherapeutics advances RedTail virotherapy platform combining BiTE and IL-15 therapies for solid tumors, aiming to overcome immunosuppressive microenvironments. IND submission planned for 2026.
CLDIsolid tumorsRedTail platform